Clinical Trials Directory

Trials / Completed

CompletedNCT00876616

Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis

An Multi-site, Open, Prospective Study to Assess the Efficacy and Safety of Multi-target Therapy in the Treatment of Class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ Lupus Nephritis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
362 (actual)
Sponsor
Zhi-Hong Liu, M.D. · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess the efficacy and safety of multi-target therapy in the treatment of class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ lupus nephritis.

Detailed description

1. To assess the efficacy of FK506 combined with MMF vs intravenous cyclophosphamide (CTX) pulses in treatment of class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ Lupus Nephritis (LN). 2. To investigate the safety and tolerability of FK506 combined with MMF vs intravenous CTX pulses in the treatment of class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ LN.

Conditions

Interventions

TypeNameDescription
DRUGTacrolimus+Mycophenolate mofetilFK506 4mg/d,MMF 1.0g/d
DRUGCyclophosphamideCTX 0.75g/m2 BSA

Timeline

Start date
2009-04-01
Primary completion
2011-05-01
Completion
2012-02-01
First posted
2009-04-07
Last updated
2013-08-29

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT00876616. Inclusion in this directory is not an endorsement.